Hemophilia

February 10th 2025

The context matters — and it is not a matter of semantics.

December 23rd 2024

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older.

October 11th 2024

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.

December 21st 2023

Men with severe or moderately severe hemophilia B continue to display low bleeding rates and very little use of replacement therapies for at least three years following a single dose of the approved gene therapy hemgenix.